Nuvelo announced preclinical data demonstrating the mechanism of action and the potent therapeutic activity of NU206 in chemotherapy or radiation-induced oral mucositis models.
Ads by Google
Drug Clinical Trials
Isis Pharmaceuticals announced additional results from its ongoing Phase 2 open-label extension study of mipomersen in patients with familial hypercholesterolemia.
Napo Pharmaceuticals announces positive results of a successfully completed Phase 2 trial for CRO-ID conducted by Glenmark Pharmaceuticals.
Spectral Diagnostics's Endotoxin Activity Assay will be used to measure endotoxin levels during the enrolment of patients in a Phase III sub study, part of a multinational clinical trial evaluating the safety and effectiveness of a treatment for severe sepsis.
Pharmaxis' Phase II clinical trial in children with cystic fibrosis demonstrated excellent lung function improvement following three months treatment with Bronchitol that matched that achieved by the current marketed product rhDNase.
A patient's willingness to participate in a clinical trial may be unaffected by the disclosure of a researcher's financial interests in the study, unless the amount of money a researcher stands to earn depends on the results of the trial.
The trial is an eight-week, double-blind, placebo-controlled, exploratory study being conducted in 20 sites in the United States. It will assess the efficacy and tolerability of rufinamide in up to 230 patients with general anxiety disorder, as measured by multiple psychometric assessment tools. Patients randomized to rufinamide will receive 250mg twice a day for one week followed by 500mg twice a day for seven weeks. The trial design was guided by the encouraging results of a proof-of-concept study announced in January 2008.
IntelliPharmaCeutics announces significant results from a recently completed pilot clinical trial for its new abuse-resistant, alcohol-resistant once-a-day oral oxycodone formulation by its operating company IntelliPharmaCeutics.
Aeterna Zentaris reported dosing has commenced with its flagship product candidate, cetrorelix in the second efficacy study of its Phase 3 program in benign prostatic hyperplasia (BPH), a non-cancerous enlargement of the prostate.
Nventa Biopharmaceuticals Corporation announced interim immunological data from the first two cohorts of its ongoing Phase 1 clinical trial of its lead product candidate, HspE7, in patients with cervical intraepithelial neoplasia, or CIN, a precursor to cervical cancer.
NPS Pharmaceuticals reported positive top-line results from a 28-week blinded Phase 3-extension study of GATTEX for short bowel syndrome patients who are dependent upon parenteral nutrition.
Better regulation is urgently needed for genetic tests, particularly those marketed directly to the public.
Labopharm's Phase III clinical trial for its once-daily formulation of the antidepressant trazodone achieved statistical significance for the primary efficacy endpoint.
A new gene-based technique has successfully prevented a rare craniofacial birth defect in mice and holds promise to help children with the same disorder.
NHLBI has stopped one treatment within a clinical trial of diabetes and cardiovascular disease 18 months early due to safety concerns.
Researchers have used a technique called phage display to identify and generate molecules for use in microbicide research and development.
Epistem had successfully completed a preliminary study with AstraZeneca for the use of its proprietary, minimally invasive plucked human hair biomarker technology to help steer oncology drug development.
Alexza Pharmaceuticals has initiated a Phase 1 clinical trial with AZ-007 (Staccato zaleplon). AZ-007 is an inhalation product candidate being developed for the treatment of insomnia patients who have difficulty falling asleep, including patients who awake in the middle of the night and have difficulty falling back asleep. This is the first clinical trial of AZ-007 being conducted under an IND filed
First-String Research has begun the human clinical trial process for its unique, wound-healing peptide gel.
Therapy with ustekinumab given every 12 weeks provided sustained, clinically meaningful improvement in the treatment of moderate to severe plaque psoriasis through one year.
TargeGen has started a multi-center Phase I/II clinical trial of TG101348, an oral, potent, and highly selective inhibitor of JAK2 in patients with myeloproliferative diseases.
Analyses reported a significantly lower proportion of patients receiving transfusions when ESAs treatment was initiated at hemoglobin levels between 10 to 11 grams per deciliter of blood compared with patients having Hb levels less than 10 g/dL prior to ESA treatment.
Combination of APA- 01 product candidate and the statin atorvastatin significantly reduced serum lipids and inflammatory proteins involved in the development of atherosclerosis.
Kiadis Pharma has successfully finalized its Rhitol Phase II clinical trial with the last patient completing its six month treatment cycle. Rhitol is evaluated as treatment for patients with extensive chronic Graft versus Host Disease (GvHD) intolerant or resistant to standard immunosuppressive treatment.
NPS Pharmaceuticals to begin a confirmatory Phase 3 clinical study to evaluate GATTEX in patients with short bowel syndrome.
Nuvelo has enrolled the first patient in a single-center, Phase 1 trial to determine the safety, tolerability and pharmacokinetics of escalating doses of NU172.